Key result
Systemic lupus erythematosus was associated with a higher prevalence of NCEP ATP III-defined metabolic syndrome compared to healthy controls.
Why the study?
Does systemic lupus erythematosus increase the prevalence of metabolic syndrome compared to healthy controls in South India?
Case-Control (n=164)
Does systemic lupus erythematosus increase the prevalence of metabolic syndrome compared to healthy controls in South India?
South Indian SLE patients have a higher prevalence of metabolic syndrome and an altered lipid profile compared to healthy controls, though without a significant difference in insulin resistance.
Answers are grounded in this paper and cite their sources.
May inform metabolic syndrome screening in South Indian SLE; hypothesis-generating for causality and generalizability.
Objectives To find the prevalence of metabolic syndrome in systemic lupus erythematosus (SLE) compared to controls and to identify association of metabolic syndrome with SLE disease activity and damage. Methods A total of 82 SLE and 82 healthy controls were studied. Metabolic syndrome was defined by National Cholesterol Education Program-Adult Treatment Panel III (NCEP ATP III), consensus definition for Asian Indian Adults and World Health Organisation (WHO) 1999 definition, and associations with lupus characteristics, disease activity, and damage were examined. Insulin resistance (IR) was estimated using the homeostasis model assessment for IR (HOMA-IR). Results Metabolic syndrome was present in 24.39% SLE and 12.19% controls ( p p = 0.14) by consensus definition for Asian Indians; 18.2% SLE and 7.31% controls ( p Hypertension and hypertriglyceridemia were more frequent in SLE than in controls. Mean body mass index, diastolic and systolic blood pressure, triglycerides, and total cholesterol were higher in SLE than in controls. HOMA-IR (median, range) was 1.31 (0.06–9.32) and 1.55 (0.01–7.92), p = 0.09 in SLE and controls, respectively. There was no association of metabolic syndrome with disease activity/damage and prednisolone use. SLE patients with metabolic syndrome had a significantly longer duration of disease compared to patients without metabolic syndrome. Conclusion South Indian SLE patients have higher prevalence of NCEP ATP III and WHO defined metabolic syndrome compared to healthy controls. SLE patients have an altered lipid profile, but there was no IR and no association of metabolic syndrome with disease activity or damage.
No takes yet. Share an insight, caveat, or question.
Bhat et al. (2015) conducted a case-control in Systemic lupus erythematosus (n=164). Systemic lupus erythematosus vs. Healthy controls was evaluated on Metabolic syndrome by NCEP ATP III definition. Systemic lupus erythematosus was associated with a higher prevalence of NCEP ATP III-defined metabolic syndrome compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: